Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00991068|
Recruitment Status : Completed
First Posted : October 7, 2009
Last Update Posted : March 16, 2012
|Condition or disease||Intervention/treatment||Phase|
|Carpal Tunnel Syndrome||Drug: Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch||Phase 2|
ZARS Pharma, Inc. has developed Synera® (lidocaine 70 mg and tetracaine 70 mg topical patch), a drug delivery patch that utilizes controlled heat to enhance the delivery of a local anesthetic formulation consisting of a eutectic mixture of lidocaine and tetracaine. Synera was approved by the Food and Drug Administration (FDA) on June 23, 2005 and is indicated for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodesiccation, and shave biopsy of skin lesions.
The purpose of this single center, 2-week open-label pilot study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate CTS.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Pilot Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome|
|Study Start Date :||September 2009|
|Primary Completion Date :||March 2010|
|Study Completion Date :||March 2010|
Synera topical patch
Drug: Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch
Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
- Pain intensity [ Time Frame: Screening/Day 1, Day 8, and Day 15 or early withdrawal ]
- Pain interference with activities (general, normal work, sleep) [ Time Frame: Screening/Day 1, Day 8, and Day 15 or early withdrawal ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00991068
|United States, Kansas|
|International Clinical Research Institute|
|Overland Park, Kansas, United States, 66211|
|Principal Investigator:||Srinivas Nalamachu, MD||International Clinical Research Institute|